University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Alexander Monto, M.D.

Gastroenterologist

Dr. Alexander Monto is a viral hepatitis expert with a special interest in hepatitis B and hepatitis C and antiviral therapies for these conditions. Monto currently serves as the associate director of the San Francisco Veterans Affairs Hepatitis C Resource Center at San Francisco Veterans Hospital. In addition to caring for patients, Monto also is involved in clinical trials investigating new drugs for viral hepatitis. His previous research on hepatitis has been widely published in medical journals and he has been invited to lecture on his work at various medical conferences. Monto also serves as the medical editor of the National Veterans Affairs Hepatitis C Web site and is a member of numerous professional organizations, such as the American Association for the Study of Liver Disease (AASLD) and American Gastroenterology Association.

Monto earned his medical degree from Columbia University, College of Physicians and Surgeons, New York and completed residencies in internal medicine at Columbia Presbyterian Medical Center, New York and Massachusetts General Hospital, Boston. He then went on to complete a fellowship in gastroenterology at UCSF before joining the faculty in 2001, where he holds the position of assistant clinical professor of medicine.

Conditions & Treatments

More about Alexander Monto

Additional Languages

Spanish

Education

Columbia College of Physicians and Surgeons 1995

Residencies

Massachusetts General Hospital, Internal Medicine 1995

Fellowships

UCSF Medical Center, Gastroenterology 1995

Selected Research and Publications

  1. Saxena V, Monto A, Terrault N. Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply. Aliment Pharmacol Ther. 2014 Jun; 39(12):1428.
  2. Somsouk M, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R. Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdom Imaging. 2014 Apr; 39(2):251-6.
  3. Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014 May; 39(10):1213-24.
  4. Zissen MH, Wang ZJ, Yee J, Aslam R, Monto A, Yeh BM. Contrast-Enhanced CT Quantification of the Hepatic Fractional Extracellular Space: Correlation With Diffuse Liver Disease Severity. AJR Am J Roentgenol. 2013 Dec; 201(6):1204-10.
  5. Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A. Nonresponse to interferon-a based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013; 8(4):e61568.
  6. Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One. 2013; 8(2):e55776.
  7. Yee RM, Lehil MS, Rongey C, Shen H, Cozen ML, Monto A, Ryan JC. Impaired lymphocyte reactivity measured by immune function testing in untransplanted patients with cirrhosis. Clin Vaccine Immunol. 2013 Apr; 20(4):526-9.
  8. Sun B, Abadjian L, Rempel H, Monto A, Pulliam L. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr. 2013 Feb 1; 62(2):190-6.
  9. Monto A, Ryan J. Is IL28B genotype associated with more than one aspect of viral clearance? Hepatology. 2012 Dec; 56(6):2414-6.
  10. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012 May; 107(5):669-89; quiz 690.
  11. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, GŁnthard HF, Wong JK. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3035-40.
  12. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol. 2011 Oct; 52(2):133-7.
  13. Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci. 2011 Aug; 56(8):2439-48.
  14. Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One. 2011; 6(5):e20104.
  15. Babik JM, Cohan D, Monto A, Hartigan-O'Connor DJ, McCune JM. The human fetal immune response to hepatitis C virus exposure in utero. J Infect Dis. 2011 Jan 15; 203(2):196-206.
  16. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011 Mar; 172(1-2):27-31.
  17. Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg. 2010 Nov; 200(5):659-64.
  18. Bacchetti P, Boylan RD, Terrault NA, Monto A, Berenguer M. Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat. 2010; 6(1):Article 7.
  19. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol. 2010 May; 105(5):989-1004; quiz 988, 1005.
  20. Chapko MK, Yee HS, Monto A, Dominitz JA. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. Vaccine. 2010 Feb 17; 28(7):1726-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.